DK0800536T3 - Rekombinante IL-5 antagonister, der er nyttige til behandling af IL-5-medierede lidelser - Google Patents

Rekombinante IL-5 antagonister, der er nyttige til behandling af IL-5-medierede lidelser

Info

Publication number
DK0800536T3
DK0800536T3 DK95944692T DK95944692T DK0800536T3 DK 0800536 T3 DK0800536 T3 DK 0800536T3 DK 95944692 T DK95944692 T DK 95944692T DK 95944692 T DK95944692 T DK 95944692T DK 0800536 T3 DK0800536 T3 DK 0800536T3
Authority
DK
Denmark
Prior art keywords
treatment
pct
recombinant
mediated disorders
antagonists useful
Prior art date
Application number
DK95944692T
Other languages
Danish (da)
English (en)
Inventor
Irwin M Chaiken
Mitchell Stuart Gross
Stephen Dudley Holmes
Robert S Ames
Edward Robert Appelbaum
Richard M Cook
Lynette Jane Mcmillan
Timothy Wayne Theisen
Original Assignee
Smithkline Beecham Corp
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27408594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0800536(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/470,110 external-priority patent/US5693323A/en
Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of DK0800536T3 publication Critical patent/DK0800536T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5409—IL-5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
DK95944692T 1994-12-23 1995-12-22 Rekombinante IL-5 antagonister, der er nyttige til behandling af IL-5-medierede lidelser DK0800536T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36313194A 1994-12-23 1994-12-23
US08/470,110 US5693323A (en) 1994-12-23 1995-06-06 Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US08/467,420 US5683892A (en) 1994-12-23 1995-06-06 DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
PCT/US1995/017082 WO1996021000A2 (en) 1994-12-23 1995-12-22 Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders

Publications (1)

Publication Number Publication Date
DK0800536T3 true DK0800536T3 (da) 2007-04-02

Family

ID=27408594

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95944692T DK0800536T3 (da) 1994-12-23 1995-12-22 Rekombinante IL-5 antagonister, der er nyttige til behandling af IL-5-medierede lidelser

Country Status (21)

Country Link
US (1) US6129913A (enExample)
EP (1) EP0800536B1 (enExample)
JP (2) JP2001523083A (enExample)
CN (1) CN100391977C (enExample)
AT (1) ATE346867T1 (enExample)
AU (1) AU708951B2 (enExample)
BR (1) BR9510499B1 (enExample)
CA (1) CA2208503C (enExample)
CZ (1) CZ297045B6 (enExample)
DE (1) DE69535319T2 (enExample)
DK (1) DK0800536T3 (enExample)
ES (1) ES2277336T3 (enExample)
FI (1) FI119374B (enExample)
HU (1) HU222992B1 (enExample)
LU (1) LU92912I2 (enExample)
MX (1) MX9704779A (enExample)
NL (1) NL300787I2 (enExample)
NO (2) NO324181B1 (enExample)
NZ (1) NZ301916A (enExample)
PL (1) PL194312B1 (enExample)
WO (1) WO1996021000A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) * 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
EP2275540B1 (en) * 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
ES2327830T3 (es) * 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
EP1682571A4 (en) * 2003-10-27 2006-12-06 Medvet Science Pty Ltd BICOORDIN PATTERN AND METHODS OF USE
KR101206318B1 (ko) * 2004-10-28 2012-11-29 교와 핫꼬 기린 가부시키가이샤 자궁 내막증 치료제
WO2008134724A2 (en) 2007-04-30 2008-11-06 Smithkline Beecham Corporation Methods for administering anti-il-5 antibodies
JP4335286B2 (ja) 2008-02-08 2009-09-30 ファナック株式会社 部品保護機能を備えたロボット制御装置及びロボット制御方法
KR20100134702A (ko) 2008-03-28 2010-12-23 글락소스미스클라인 엘엘씨 치료 방법
CA2787070A1 (en) * 2010-01-28 2011-08-04 Ian Kirby Cd127 binding proteins
AU2011349049B2 (en) 2010-12-22 2016-08-11 Teva Pharmaceuticals Australia Pty Ltd Modified antibody with improved half-life
ES3053874T3 (en) 2015-08-24 2026-01-27 Glaxosmithkline Ip No 2 Ltd Biopharmaceutical compositions
WO2017173091A1 (en) * 2016-03-30 2017-10-05 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
EA201991552A1 (ru) * 2016-12-23 2020-01-09 Сефалон, Инк. Анти-il-5 антитела
SMT202600240T1 (it) * 2017-05-26 2026-07-16 Glaxosmithkline Ip Dev Ltd Composizioni biofarmaceutiche e metodi correlati
WO2019062831A1 (zh) 2017-09-29 2019-04-04 江苏恒瑞医药股份有限公司 Il-5抗体、其抗原结合片段及医药用途
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途
CN113366016B (zh) * 2018-12-12 2022-12-16 上海开拓者生物医药有限公司 抗人白细胞介素5(il-5)单克隆抗体及其应用
JP7641908B2 (ja) * 2019-03-29 2025-03-07 ジエンス ヘンルイ メデイシンカンパニー リミテッド Ｉｌ－５に対する抗体を含有する医薬組成物及びその使用
AU2024406222A1 (en) 2023-12-20 2026-06-04 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8800397D0 (en) * 1988-01-08 1988-02-10 Sandoz Ltd Improvements in/relating to organic compounds
US5096704A (en) * 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
WO1990004979A2 (en) * 1988-11-03 1990-05-17 Schering Corporation Method of preventing or reducing eosinophilia
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ZA929328B (en) * 1991-12-02 1993-07-20 Fluor Corp Apparatus and method for economic use of excess compressed air when firing low caloric-value gas in a combustion gas turbine.
SG49597A1 (en) * 1992-02-06 1998-06-15 Schering Corp Design cloning and expression of humanized monoclonal antibodies against human interleukin-5
JPH06141885A (ja) * 1992-11-05 1994-05-24 Chemo Sero Therapeut Res Inst モノクローナル抗体
WO1995014040A1 (en) * 1993-11-19 1995-05-26 Baylor College Of Medicine Monoclonal antibodies specific for human interleukin-5
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US5783184A (en) * 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
WO2001012646A1 (en) * 1999-08-19 2001-02-22 Smithkline Beecham Corporation Sialoadhesin factor-1 agonist and antagonist antibodies

Also Published As

Publication number Publication date
PL194312B1 (pl) 2007-05-31
FI119374B (fi) 2008-10-31
HK1003651A1 (en) 1998-11-06
CN1175263A (zh) 1998-03-04
US6129913A (en) 2000-10-10
NL300787I1 (enExample) 2016-04-05
BR9510499B1 (pt) 2009-05-05
EP0800536B1 (en) 2006-11-29
HUT78055A (hu) 1999-07-28
AU708951B2 (en) 1999-08-19
DE69535319T2 (de) 2007-07-19
DE69535319D1 (de) 2007-01-11
NO324181B1 (no) 2007-09-03
FI972703L (fi) 1997-08-22
NZ301916A (en) 1999-05-28
NO2015027I2 (no) 2016-01-04
CN100391977C (zh) 2008-06-04
NO972913L (no) 1997-08-19
NO972913D0 (no) 1997-06-20
MX9704779A (es) 1997-09-30
PL321088A1 (en) 1997-11-24
FI972703A0 (fi) 1997-06-23
NL300787I2 (enExample) 2016-04-05
CZ196397A3 (en) 1997-10-15
BR9510499A (pt) 1999-03-30
CA2208503A1 (en) 1996-07-11
NO2015027I1 (no) 2015-12-18
ES2277336T3 (es) 2007-07-01
JP2008029355A (ja) 2008-02-14
WO1996021000A2 (en) 1996-07-11
EP0800536A2 (en) 1997-10-15
CA2208503C (en) 2009-12-01
CZ297045B6 (cs) 2006-08-16
EP0800536A4 (en) 2004-12-01
ATE346867T1 (de) 2006-12-15
WO1996021000A3 (en) 1996-09-06
AU4745096A (en) 1996-07-24
JP2001523083A (ja) 2001-11-20
HU222992B1 (hu) 2004-01-28
LU92912I2 (fr) 2016-02-16

Similar Documents

Publication Publication Date Title
NO2015027I2 (no) Mepolizumab
BR0008688A (pt) Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18
SE9604793D0 (sv) New polymorphs
ES2108120T3 (es) Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
DK0771197T3 (da) Anvendelse af heterocykliske forbindelser som dopamin-D3-ligander
DK0726765T3 (da) Apparat og fremgangsmåde til fremstilling af faste former med styret frigivelse af den aktive bestanddel
LU91271I2 (fr) Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI)
DE69132141D1 (de) Neuroprotective indolone und verwandte derivate
YU7797A (sh) Kombinovana terapija za osteoporozu
BR9910180A (pt) Composição farmacêutica, processos para o tratamento de uma condição associada com a transmissão reduzida de nicotina, para identificação de um modulador positivo de um agonista receptor nicotìnico e para identificação de um composto, composto, e, uso de um modulador positivo de um agonista receptor nicotìnico
EP1749840A3 (en) Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders
DK0712311T3 (da) Antiglucocorticoidsteroider til behandling af angstlidelser
DE69836678D1 (de) Chinolin- und chinazolinderivate als antagonisten des corticotropin freisetzenden faktors (crf)
DK0989973T3 (da) Chalconer med antiproliferativ aktivitet
IL117209A (en) 1-aryl-2-acylamino-ethane compounds and pharmaceutical compositions containing them
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
ATE78162T1 (de) 5-ht3-rezeptor-antagonisten zur behandlung von husten und bronchokonstriktion.
NO952427L (no) Metode for behandling av kronisk prostatitt med 17 substituerte karbamoyl-4-aza-5
ES2163001T3 (es) Nuevos derivados de borneol, procedimiento para su preparacion y su utilizacion farmaceutica.
SE9404438D0 (sv) New process
ATE184650T1 (de) Verfahren zur herstellung von spirolaxin und spirolaxinmethylether